# Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

> **NCT00568633** · PHASE3 · TERMINATED · sponsor: **Stanford University** · enrollment: 58 (actual)

## Conditions studied

- Leukemia, Myeloid
- Leukemia
- Acute Myeloid Leukemia (AML)

## Interventions

- **PROCEDURE:** Allogeneic HSCT
- **DRUG:** Anti-thymocyte globulin (ATG)
- **DRUG:** Cyclosporine (CSP)
- **DRUG:** Mycophenolate mofetil (MMF)
- **RADIATION:** Total lymphoid irradiation (TLI)
- **DRUG:** Methylprednisolone sodium succinate
- **DRUG:** Best standard care

## Key facts

- **NCT ID:** NCT00568633
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2015-12-31
- **Final completion:** 2015-12-31
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568633, "Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00568633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*